Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website Xinhua Silk Road - Belt and Road Portal, China's silk road economic belt and 21st Century Maritime Silk Road Website
Subscribe CustomBlackClose

Belt & Road Weekly Subscription Form

download_pop

Research ReportCustomBlackClose

The full edition of the report is available at Xinhua Silk Road Database. You can click the “Table of Content” to have a general understanding of it.

Click on the button below to create your account and get immediate access to thousands of articles.

Start a Free Trial

Xinhua Silk Road Database
International Relation

China's Sinopharm COVID-19 vaccine likely conducive to global vaccine accessibility: Indian newspaper

May 13, 2021


Abstract : The WHO last week validated China's Sinopharm COVID-19 vaccine for emergency use, a move set to further expand global vaccine accessibility.

A worker transports Sinopharm COVID-19 vaccine at the Phnom Penh International Airport in Phnom Penh, Cambodia, April 28, 2021. (Photo by Phearum/Xinhua)

NEW DELHI, May 13 (Xinhua) -- China's Sinopharm COVID-19 vaccine, the first non-Western vaccine supported by the World Health Organization (WHO), is likely to be used in the COVAX program, which provides vaccines to low- and middle-income countries, reported the Indian Express newspaper Thursday.

The WHO last week validated the China-developed vaccine for emergency use, a move set to further expand global vaccine accessibility.

According to the WHO, Sinopharm has an efficacy of about 79 percent for symptomatic and hospitalised disease for all age groups. However, it notes that since few adults aged over 60 were enrolled, the efficacy in the age group is not clear, said an article in the paper.

The Sinopharm vaccine is an inactivated coronavirus vaccine, which takes the disease-carrying virus (SARS-CoV-2) and kill it utilizing heat, chemicals or radiation, it said, quoting the WHO as saying that these vaccines take longer to make and might need two or three jabs to be administered.

The WHO has not recommended an upper age limit on the use of this vaccine "because preliminary data and supportive immunogenicity data suggest the vaccine is likely to have a protective effect in older persons. There is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations," said the report.

The WHO has recommended that the vaccine be administered to adults aged 18 and above in a two-dose schedule with a gap of three to four weeks, it said.

Scan the QR code and push it to your mobile phone

Keyword: WHO Sinopharm COVID-19 vaccine

Reading:

Foreign investors confident in Hainan's offshore duty-free industry on spurring consumption transformation and upgrading

CICPE strong booster for construction of Hainan int'l tourism consumption center

Xinhua Headlines: Int'l community casts vote of confidence in Belt and Road

​RMB appreciation boosts attractiveness of assets investment

China's first consumer products expo a magnet for international companies

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to [email protected] and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial

Ask Us A Question belt & road login close

If you have any questions, please enter them in the box below.

Identifying code Reload

Write to Us belt & road login close

Do you want to be a contributor to Xinhua Silk Road and tell us your Belt & Road story? Send your articles to silkroadweekly@xinhua.org and share your stories with more people.

Click on the button below to create your account and get im http://img.silkroad.news.cn/templates/silkroad/en2017te access to thousands of articles.

Start a Free Trial